Pliant Therapeutics Inc
NASDAQ:PLRX
Pliant Therapeutics Inc
EPS (Diluted)
Pliant Therapeutics Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pliant Therapeutics Inc
NASDAQ:PLRX
|
EPS (Diluted)
-$2
|
CAGR 3-Years
6%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
EPS (Diluted)
$11
|
CAGR 3-Years
18%
|
CAGR 5-Years
15%
|
CAGR 10-Years
7%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
EPS (Diluted)
$3
|
CAGR 3-Years
5%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
14%
|
|
|
Pfizer Inc
NYSE:PFE
|
EPS (Diluted)
$1
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
2%
|
|
|
Merck & Co Inc
NYSE:MRK
|
EPS (Diluted)
$7
|
CAGR 3-Years
8%
|
CAGR 5-Years
21%
|
CAGR 10-Years
17%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
EPS (Diluted)
$22
|
CAGR 3-Years
49%
|
CAGR 5-Years
28%
|
CAGR 10-Years
26%
|
|
Pliant Therapeutics Inc
Glance View
Pliant Therapeutics, Inc. engages in the business of developing and commercializing novel therapies for fibrotic diseases. The company is headquartered in South San Francisco, California and currently employs 91 full-time employees. The company went IPO on 2020-06-03. The firm is focused on discovering and developing therapies for the treatment of fibrosis and related diseases. The company focuses in treating fibrosis by inhibiting integrin-mediated activation of transforming growth factor beta (TGF-B). Its lead product candidate, PLN-74809, is an oral small-molecule, dual-selective inhibitor of avß6 and avB1. The Company’s second product candidate, PLN-1474, is a small-molecule, selective inhibitor of avB1 for treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition to its clinical programs, it is developing additional preclinical integrin-based programs. The first preclinical program is oncology program. Its second preclinical program is an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor being developed for treatment of muscular dystrophies, including duchenne muscular dystrophy.
See Also
What is Pliant Therapeutics Inc's EPS (Diluted)?
EPS (Diluted)
-2.4
USD
Based on the financial report for Dec 31, 2025, Pliant Therapeutics Inc's EPS (Diluted) amounts to -2.4 USD.
What is Pliant Therapeutics Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
-4%
Over the last year, the EPS (Diluted) growth was 30%. The average annual EPS (Diluted) growth rates for Pliant Therapeutics Inc have been 6% over the past three years , -4% over the past five years .
